GLP-1 Review Board tracks FDA-approved and compounded GLP-1 programs — published pricing, provider process, pharmacy disclosures, state availability, regulatory risk, safety claims, and hidden fees. We lead with where the rules stand, because in 2026 that is the part most price pages leave out.
Shortage-era mass compounding is not the market it was in 2023–2024. Before comparing any compounded program, understand what changed.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.
Tables sort by published price or alphabetically — never by a proprietary trust score. We don’t publish vendor copy as our own findings, don’t place any provider first because of a referral relationship, and never imply a compounded product equals the branded drug. Every price carries the date we checked it.